MEDI 0382

Drug Profile

MEDI 0382

Alternative Names: MEDI0382

Latest Information Update: 16 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MedImmune
  • Class Antihyperglycaemics; Obesity therapies
  • Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 16 Aug 2017 MedImmune plans a phase II trial for Obesity and Type-2 diabetes mellitus) (NCT03244800)
  • 03 Aug 2017 AstraZeneca plans a phase II trial for Type-2 diabetes mellitus and Obesity in USA, Canada, Czech Republic, Germany, Hungary, Mexico, Russia and Slovakia (NCT03235050)
  • 03 Aug 2017 MedImmune plans a pharmacokinetic phase I trial (NCT03235375)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top